- Home
- IKNA vs ACOG Comparison
IKNA vs ACOG Comparison
Compare IKNA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- ACOG
- Stock Information
- Founded
- IKNA 2016
- ACOG 2000
- Country
- IKNA United States
- ACOG Canada
- Employees
- IKNA N/A
- ACOG N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- ACOG
- Sector
- IKNA Health Care
- ACOG
- Exchange
- IKNA Nasdaq
- ACOG Nasdaq
- Market Cap
- IKNA 81.6M
- ACOG 91.6M
- IPO Year
- IKNA 2021
- ACOG N/A
- Fundamental
- Price
- IKNA $1.45
- ACOG $6.11
- Analyst Decision
- IKNA Buy
- ACOG
- Analyst Count
- IKNA 2
- ACOG 0
- Target Price
- IKNA $3.00
- ACOG N/A
- AVG Volume (30 Days)
- IKNA 134.5K
- ACOG 135.6K
- Earning Date
- IKNA 03-11-2025
- ACOG 11-15-2024
- Dividend Yield
- IKNA N/A
- ACOG N/A
- EPS Growth
- IKNA N/A
- ACOG N/A
- EPS
- IKNA N/A
- ACOG N/A
- Revenue
- IKNA $659,000.00
- ACOG N/A
- Revenue This Year
- IKNA N/A
- ACOG N/A
- Revenue Next Year
- IKNA N/A
- ACOG N/A
- P/E Ratio
- IKNA N/A
- ACOG N/A
- Revenue Growth
- IKNA N/A
- ACOG N/A
- 52 Week Low
- IKNA $1.22
- ACOG $4.66
- 52 Week High
- IKNA $1.94
- ACOG $7.00
- Technical
- Relative Strength Index (RSI)
- IKNA 36.12
- ACOG N/A
- Support Level
- IKNA $1.45
- ACOG N/A
- Resistance Level
- IKNA $1.53
- ACOG N/A
- Average True Range (ATR)
- IKNA 0.06
- ACOG 0.00
- MACD
- IKNA -0.00
- ACOG 0.00
- Stochastic Oscillator
- IKNA 23.53
- ACOG 0.00
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.